Ergoteles’s Spero Therapeutics SPRO Stock Holding History

Ergoteles’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-102,408	Closed	-$76K	–	1962
2022 Q2	$76K	Buy	+102,408	New	+$298K	﹤0.01%	1539

Other funds holding SPRO

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Ergoteles's SPRO Position: Q3 2022 in Review

Ergoteles sold out of Spero Therapeutics (SPRO) in Q3 2022, closing a stake of 102,408 shares — an estimated $76K sold.

Ergoteles first reported a position in SPRO in Q2 2022 and held it in 1 quarter. The position peaked at $76K in Q2 2022. 69 funds tracked by Wall St. Rank hold SPRO as of Q3 2022.

Ergoteles reported no remaining Spero Therapeutics position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 102,408 Spero Therapeutics shares in Q3 2022, an estimated $76K.
Ergoteles first reported a position in Spero Therapeutics in Q2 2022 and held it in 1 quarter.
Ergoteles's Spero Therapeutics position peaked at $76K in Q2 2022.
69 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.